Agios Pharmaceuticals Inc (AGIO) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-1.47 earnings per share for the quarter, missing the analyst consensus estimate by $-0.17. Analysts had a consensus of $-1.30. The company posted revenue of $6.97 million in the period, compared to analysts expectations of $41.37 million. The company’s revenue was down -47.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.85 EPS.
Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Agios Pharmaceuticals Inc was Upgraded by JP Morgan to ” Overweight” on Jun 13, 2016. Company shares were Reiterated by SunTrust on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .Company shares were Reiterated by Sun Trust Rbsn Humphrey on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .
Agios Pharmaceuticals Inc closed down -0.79 points or -1.73% at $44.9 with 4,23,581 shares getting traded on Tusday. Post opening the session at $45.72, the shares hit an intraday low of $43.33 and an intraday high of $46.19 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jul 27, 2016, Lewis Clayton Jr. Cantley (director) sold 2,504 shares at $42.79 per share price. According to the SEC, on Jun 10, 2016, Scott Biller (Chief Scientific Officer) sold 27,500 shares at $65.00 per share price. On Dec 17, 2015, John Duncan Higgons (Chief Operating Officer) sold 20,000 shares at $50.09 per share price, according to the Form-4 filing with the securities and exchange commission.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.